| 中文名 | 6-(2-(3,4-二乙氧基苯基)噻唑-4-基)甲酸吡啶 |
|---|---|
| 英文名 | 6-[2-(3,4-diethoxyphenyl)-1,3-thiazol-4-yl]pyridine-2-carboxylic acid |
| 英文别名 |
Tetomilast
2-Pyridinecarboxylic acid, 6-[5-(3,4-diethoxyphenyl)-3-thienyl]- UNII-S6RXB5KF56 6-[5-(3,4-Diethoxyphenyl)-3-thienyl]-2-pyridinecarboxylic acid 6-[2-(3,4-diethoxypheny)-1,3-thiazol-4-yl]pyridine-2-carboxylic acid |
| 描述 | 强的松(OPC-6535)是一种PDE4抑制剂,具有治疗炎症性肠病(IBD)和慢性阻塞性肺疾病(COPD)的潜力。 |
|---|---|
| 相关类别 | |
| 参考文献 |
| 密度 | 1.2±0.1 g/cm3 |
|---|---|
| 沸点 | 526.1±50.0 °C at 760 mmHg |
| 分子式 | C19H18N2O4S |
| 分子量 | 369.434 |
| 闪点 | 272.0±30.1 °C |
| 精确质量 | 369.103485 |
| PSA | 109.78000 |
| LogP | 4.39 |
| 蒸汽压 | 0.0±1.5 mmHg at 25°C |
| 折射率 | 1.601 |
| 储存条件 | 2-8°C,密封,干燥 |
| 海关编码 | 2934100090 |
|---|
|
~78%
145739-56-6 |
| 文献:OTSUKA PHARMACEUTICAL CO., LTD. Patent: WO2007/119496 A1, 2007 ; Location in patent: Page/Page column 65-68 ; |
|
~92%
145739-56-6 |
| 文献:Chihiro; Nagamoto; Takemura; Kitano; Komatsu; Sekiguchi; Tabusa; Mori; Tominaga; Yabuuchi Journal of Medicinal Chemistry, 1995 , vol. 38, # 2 p. 353 - 358 |
|
~%
145739-56-6 |
| 文献:Chihiro; Nagamoto; Takemura; Kitano; Komatsu; Sekiguchi; Tabusa; Mori; Tominaga; Yabuuchi Journal of Medicinal Chemistry, 1995 , vol. 38, # 2 p. 353 - 358 |
|
~%
145739-56-6 |
| 文献:Chihiro; Nagamoto; Takemura; Kitano; Komatsu; Sekiguchi; Tabusa; Mori; Tominaga; Yabuuchi Journal of Medicinal Chemistry, 1995 , vol. 38, # 2 p. 353 - 358 |
|
~%
145739-56-6 |
| 文献:Chihiro; Nagamoto; Takemura; Kitano; Komatsu; Sekiguchi; Tabusa; Mori; Tominaga; Yabuuchi Journal of Medicinal Chemistry, 1995 , vol. 38, # 2 p. 353 - 358 |
|
~%
145739-56-6 |
| 文献:Chihiro; Nagamoto; Takemura; Kitano; Komatsu; Sekiguchi; Tabusa; Mori; Tominaga; Yabuuchi Journal of Medicinal Chemistry, 1995 , vol. 38, # 2 p. 353 - 358 |
| 上游产品 5 | |
|---|---|
| 下游产品 0 | |
| 海关编码 | 2934100090 |
|---|---|
| 中文概述 | 2934100090. 结构上含有一个非稠合噻唑环的化合物(不论是否氢化). 增值税率:17.0%. 退税率:9.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0% |
| 申报要素 | 品名, 成分含量, 用途 |
| Summary | 2934100090 other compounds containing an unfused thiazole ring (whether or not hydrogenated) in the structure VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:20.0% |